vs
Side-by-side financial comparison of V F CORP (VFC) and Zoetis (ZTS). Click either name above to swap in a different company.
V F CORP is the larger business by last-quarter revenue ($2.9B vs $2.4B, roughly 1.2× Zoetis). Zoetis runs the higher net margin — 25.3% vs 10.5%, a 14.8% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (3.0% vs 1.5%). V F CORP produced more free cash flow last quarter ($977.9M vs $732.0M). Over the past eight quarters, V F CORP's revenue compounded faster (10.1% CAGR vs 4.4%).
The F. W. Woolworth Company was a retail company and one of the pioneers of the five-and-dime store. It was among the most successful American and international five-and-dime businesses, setting trends and creating the modern retail model that stores worldwide follow today.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
VFC vs ZTS — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.9B | $2.4B |
| Net Profit | $300.8M | $603.0M |
| Gross Margin | 56.6% | 70.2% |
| Operating Margin | 10.1% | 31.9% |
| Net Margin | 10.5% | 25.3% |
| Revenue YoY | 1.5% | 3.0% |
| Net Profit YoY | 79.3% | 3.8% |
| EPS (diluted) | $0.76 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.9B | $2.4B | ||
| Q3 25 | $2.8B | $2.4B | ||
| Q2 25 | $1.8B | $2.5B | ||
| Q1 25 | $2.0B | $2.2B | ||
| Q4 24 | $2.8B | $2.3B | ||
| Q3 24 | $2.8B | $2.4B | ||
| Q2 24 | $1.9B | $2.4B | ||
| Q1 24 | $2.4B | $2.2B |
| Q4 25 | $300.8M | $603.0M | ||
| Q3 25 | $189.8M | $721.0M | ||
| Q2 25 | $-116.4M | $718.0M | ||
| Q1 25 | $-150.8M | $631.0M | ||
| Q4 24 | $167.8M | $581.0M | ||
| Q3 24 | $52.2M | $682.0M | ||
| Q2 24 | $-258.9M | $624.0M | ||
| Q1 24 | $-418.3M | $599.0M |
| Q4 25 | 56.6% | 70.2% | ||
| Q3 25 | 52.2% | 71.5% | ||
| Q2 25 | 53.9% | 73.6% | ||
| Q1 25 | 52.7% | 72.0% | ||
| Q4 24 | 56.3% | 69.5% | ||
| Q3 24 | 52.2% | 70.6% | ||
| Q2 24 | 52.0% | 71.7% | ||
| Q1 24 | 48.4% | 70.6% |
| Q4 25 | 10.1% | 31.9% | ||
| Q3 25 | 11.2% | 37.0% | ||
| Q2 25 | -4.9% | 36.7% | ||
| Q1 25 | 2.2% | 36.5% | ||
| Q4 24 | 8.0% | 31.6% | ||
| Q3 24 | 9.9% | 36.6% | ||
| Q2 24 | -12.6% | 33.0% | ||
| Q1 24 | -15.0% | 34.1% |
| Q4 25 | 10.5% | 25.3% | ||
| Q3 25 | 6.8% | 30.0% | ||
| Q2 25 | -6.6% | 29.2% | ||
| Q1 25 | -7.5% | 28.4% | ||
| Q4 24 | 5.9% | 25.1% | ||
| Q3 24 | 1.9% | 28.6% | ||
| Q2 24 | -13.6% | 26.4% | ||
| Q1 24 | -17.6% | 27.4% |
| Q4 25 | $0.76 | $1.37 | ||
| Q3 25 | $0.48 | $1.63 | ||
| Q2 25 | $-0.30 | $1.61 | ||
| Q1 25 | $-0.37 | $1.41 | ||
| Q4 24 | $0.43 | $1.29 | ||
| Q3 24 | $0.13 | $1.50 | ||
| Q2 24 | $-0.67 | $1.37 | ||
| Q1 24 | $-1.07 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.5B | — |
| Total DebtLower is stronger | $3.6B | — |
| Stockholders' EquityBook value | $1.8B | $3.3B |
| Total Assets | $10.4B | $15.5B |
| Debt / EquityLower = less leverage | 1.99× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.5B | — | ||
| Q3 25 | $419.1M | $2.1B | ||
| Q2 25 | $642.4M | $1.4B | ||
| Q1 25 | $429.4M | $1.7B | ||
| Q4 24 | $1.4B | $2.0B | ||
| Q3 24 | $492.2M | $1.7B | ||
| Q2 24 | $637.4M | $1.6B | ||
| Q1 24 | $674.6M | $2.0B |
| Q4 25 | $3.6B | — | ||
| Q3 25 | $3.5B | — | ||
| Q2 25 | $3.6B | — | ||
| Q1 25 | $3.4B | — | ||
| Q4 24 | $3.9B | — | ||
| Q3 24 | $4.0B | — | ||
| Q2 24 | $3.9B | — | ||
| Q1 24 | $4.7B | — |
| Q4 25 | $1.8B | $3.3B | ||
| Q3 25 | $1.5B | $5.4B | ||
| Q2 25 | $1.3B | $5.0B | ||
| Q1 25 | $1.5B | $4.7B | ||
| Q4 24 | $1.7B | $4.8B | ||
| Q3 24 | $1.4B | $5.2B | ||
| Q2 24 | $1.4B | $5.0B | ||
| Q1 24 | $1.7B | $5.1B |
| Q4 25 | $10.4B | $15.5B | ||
| Q3 25 | $10.6B | $15.2B | ||
| Q2 25 | $10.2B | $14.5B | ||
| Q1 25 | $9.4B | $14.1B | ||
| Q4 24 | $10.6B | $14.2B | ||
| Q3 24 | $12.2B | $14.4B | ||
| Q2 24 | $11.5B | $14.2B | ||
| Q1 24 | $11.6B | $14.3B |
| Q4 25 | 1.99× | — | ||
| Q3 25 | 2.40× | — | ||
| Q2 25 | 2.76× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | 2.31× | — | ||
| Q3 24 | 2.86× | — | ||
| Q2 24 | 2.84× | — | ||
| Q1 24 | 2.84× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.0B | $893.0M |
| Free Cash FlowOCF − Capex | $977.9M | $732.0M |
| FCF MarginFCF / Revenue | 34.0% | 30.7% |
| Capex IntensityCapex / Revenue | 1.1% | 6.7% |
| Cash ConversionOCF / Net Profit | 3.36× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $357.6M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.0B | $893.0M | ||
| Q3 25 | $-227.0M | $938.0M | ||
| Q2 25 | $-145.5M | $486.0M | ||
| Q1 25 | $-171.1M | $587.0M | ||
| Q4 24 | $918.1M | $905.0M | ||
| Q3 24 | $-301.6M | $951.0M | ||
| Q2 24 | $19.8M | $502.0M | ||
| Q1 24 | — | $595.0M |
| Q4 25 | $977.9M | $732.0M | ||
| Q3 25 | $-253.5M | $805.0M | ||
| Q2 25 | $-173.7M | $308.0M | ||
| Q1 25 | $-193.0M | $438.0M | ||
| Q4 24 | $899.7M | $689.0M | ||
| Q3 24 | $-322.4M | $784.0M | ||
| Q2 24 | $-5.4M | $370.0M | ||
| Q1 24 | — | $455.0M |
| Q4 25 | 34.0% | 30.7% | ||
| Q3 25 | -9.0% | 33.5% | ||
| Q2 25 | -9.9% | 12.5% | ||
| Q1 25 | -9.6% | 19.7% | ||
| Q4 24 | 31.7% | 29.7% | ||
| Q3 24 | -11.7% | 32.8% | ||
| Q2 24 | -0.3% | 15.7% | ||
| Q1 24 | — | 20.8% |
| Q4 25 | 1.1% | 6.7% | ||
| Q3 25 | 0.9% | 5.5% | ||
| Q2 25 | 1.6% | 7.2% | ||
| Q1 25 | 1.1% | 6.7% | ||
| Q4 24 | 0.6% | 9.3% | ||
| Q3 24 | 0.8% | 7.0% | ||
| Q2 24 | 1.3% | 5.6% | ||
| Q1 24 | — | 6.4% |
| Q4 25 | 3.36× | 1.48× | ||
| Q3 25 | -1.20× | 1.30× | ||
| Q2 25 | — | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | 5.47× | 1.56× | ||
| Q3 24 | -5.78× | 1.39× | ||
| Q2 24 | — | 0.80× | ||
| Q1 24 | — | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
VFC
| Outdoor | $1.9B | 67% |
| Sales Channel Through Intermediary | $813.4M | 28% |
| Other | $136.3M | 5% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
